DOP085: Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn’s diseaseECCO '16 Amsterdam
2016
DOP086: Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseasesECCO '16 Amsterdam
2016
DOP087: MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn’s diseaseECCO '16 Amsterdam
2016
DOP088: Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controlsECCO '16 Amsterdam
2016
DOP089: Microbiota profiles in treatment-naïve Norwegian IBD and non-IBD patients: part of the European Union IBD character consortiumECCO '16 Amsterdam
2016
DOP090: The role of the microbiome in clinical response to golimumab in ulcerative colitisECCO '16 Amsterdam
2016
OP001: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn’s diseaseECCO '16 Amsterdam
2016
OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitisECCO '16 Amsterdam
2016
OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibody’s or clinical/biochemical markers play a more important role?ECCO '16 Amsterdam
2016
OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s diseaseECCO '16 Amsterdam
2016
OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel diseaseECCO '16 Amsterdam
2016
OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapyECCO '16 Amsterdam
2016
OP007: Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel diseaseECCO '16 Amsterdam
2016
OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitisECCO '16 Amsterdam
2016
OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel diseaseECCO '16 Amsterdam
2016
OP010: Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective studyECCO '16 Amsterdam
2016
OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)ECCO '16 Amsterdam
2016
OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programmeECCO '16 Amsterdam
2016